login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SCISPARC LTD (SPRC) Stock News
USA
- NASDAQ:SPRC -
IL0010951403
-
Common Stock
4.03
USD
+0.05 (+1.26%)
Last: 10/24/2025, 10:32:20 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SPRC Latest News, Press Relases and Analysis
All
Press Releases
3 hours ago - By: SciSparc Ltd
SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio
3 hours ago - By: SciSparc Ltd
SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio
19 hours ago - By: SciSparc Ltd
SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
19 hours ago - By: SciSparc Ltd
- Mentions:
NITO
SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
a day ago - By: SciSparc Ltd
SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
a day ago - By: SciSparc Ltd
SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
4 days ago - By: Benzinga
- Mentions:
XRTX
REPL
AZTR
HSDT
...
12 Health Care Stocks Moving In Monday's Pre-Market Session
4 days ago - By: SciSparc Ltd
SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
4 days ago - By: Clearmind Medicine Inc.
- Mentions:
CMND
Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders
4 days ago - By: SciSparc Ltd
- Mentions:
CMND
SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
9 days ago - By: Benzinga
- Mentions:
OMER
AKTX
SSKN
EYPT
...
12 Health Care Stocks Moving In Wednesday's Intraday Session
9 days ago - By: SciSparc Ltd
SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio
9 days ago - By: SciSparc Ltd
SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio
18 days ago - By: SciSparc Ltd
SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors
18 days ago - By: SciSparc Ltd
SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors
25 days ago - By: SciSparc Ltd
SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
25 days ago - By: SciSparc Ltd
SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
Please enable JavaScript to continue using this application.
